Efficacy of beetroot juice on reducing blood pressure in hypertensive adults with autosomal dominant polycystic kidney disease (BEET-PKD): study protocol for a double-blind, randomised, placebo-controlled trial

• Published in: Current controlled trials in cardiovascular medicine Vol. 24; no. 1; pp. 482 - 12
• Main Authors: Sagar, Priyanka S., Munt, Alexandra, Saravanabavan, Sayanthooran, Vahedi, Farnoosh Asghar, Elhindi, James, Nguyen, Beatrice, Chau, Katrina, Harris, David C., Lee, Vincent, Sud, Kamal, Wong, Nikki, Rangan, Gopala K.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 29.07.2023; BioMed Central; BMC
• Subjects: Antihypertensives; Beet sugar; Beetroot juice; Blood pressure; Cardiovascular disease; Care and treatment; Complications and side effects; Creatinine; Diabetes; Diagnosis; Dietary interventions in hypertension; Dietary supplements; Double-blind studies; Ethics; Health aspects; Hospitals; Hypertension; Kidney diseases; Laboratories; Medical research; Medicine; Metabolites; Nitric oxide; Polycystic kidney disease; Properties; Study Protocol; Australia; Beetroot juice; Dietary interventions in hypertension; Polycystic kidney disease
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-023-07519-2

In autosomal dominant polycystic kidney disease (ADPKD) impaired nitric oxide (NO) synthesis, in part, contributes to early-onset hypertension. Beetroot juice (BRJ) reduces blood pressure (BP) by increasing NO-mediated vasodilation. The aim of this double-blind, randomised, placebo-controlled study is to test the hypothesis that BRJ reduces systolic and diastolic clinic BP in hypertensive adults with ADPKD. Participants with ADPKD and treated hypertension (n = 60) will be randomly allocated (1:1) to receive a daily dose of either nitrate-replete (400 mg nitrate/day) or nitrate-deplete BRJ for 4 weeks. The co-primary outcomes are change in mean systolic and diastolic clinic BP before and after 4 weeks of treatment with daily BRJ. Secondary outcomes are changes in daily home BP, urinary albumin to creatinine ratio, serum and salivary nitrate/nitrite levels and serum asymmetric dimethylarginine levels before and after 4 weeks of BRJ. The effect of BRJ in ADPKD has not been previously tested. BRJ is an accessible, natural dietary supplement that, if effective, will provide a novel adjunctive approach for treating hypertension in ADPKD. ClinicalTrials.gov NCT05401409. Retrospectively registered on 27th May 2022.